The Methodist Hospital Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, The Methodist Hospital Research Institute sits in the top decile of US sponsors by registered trial count (#214 of 15,742 sponsors by registered trial count).
The Methodist Hospital Research Institute: 126 sponsored US clinical trials, 49 recruiting.
The Methodist Hospital Research Institute sponsors 126 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 48 completed. 12 of these trials are in Phase 3-4 (later-stage) and 65 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urge Incontinence, with 2 trials.
Top-decile sponsor footprint
The Methodist Hospital Research Institute ranks in the top decile of sponsors by registered trial count (#214 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
48 of 64 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
126 total, page 1 of 3
Stem Cells for Erectile Dysfunction Post RALP
NCT07048314
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
NCT07651319
Dexamethasone for Ureteral STent Symptoms (DUSTS)
NCT06930690
VR-Based Cognitive Stimulation Games for Delirium Prevention
NCT07641153
Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells
NCT06798623
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
NCT07383649
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
NCT07042685
Bone Stimulator for Spondylolysis
NCT06666608
VoiceLove Digital Therapy for Delirium in the ICU
NCT07218484
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
NCT07050771
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
NCT07182279
Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)
NCT06640491
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
NCT06887218
Non-invasive VNS in Stroke Recovery
NCT06761404
Prehabilitation for Kidney Transplant Candidates
NCT06886256
Blood Flow Restriction (BFR) Training on the Ulnar Collateral Ligament (UCL)
NCT06664827
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
NCT06286800
Home Tele Rehabilitation Therapy for Vascular Dementia
NCT06289569
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
NCT06833866
Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty
NCT06384651
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
NCT06821100
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
NCT06566443
Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction
NCT06511232
Augmenting Rehabilitation Outcomes and Functional Neuroplasticity Using Epidural Stimulation of Cervical Spinal Cord
NCT06225245
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
NCT06536413
MRI Guided Management of Occlusive Peripheral Arterial Disease
NCT06782100
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
NCT07290491
CBD for Pain Following Orthopedic Shoulder Surgery
NCT06381791
IL-2 Plus Abatacept in FTD
NCT06395038
Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity
NCT06339320
Protein Supplementation After ACL Surgery
NCT06311058
rTMS in Overactive Bladder
NCT06198439
Harnessing Neuroplasticity of Postural Sensorimotor Networks Using Non-Invasive Spinal Neuromodulation to Maximize Functional Recovery After Spinal Cord Injury
NCT06213012
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
NCT06072703
Venous Ethanol for Ventricular Tachycardia
NCT05511246
Systemic and Central Inflammation in AD
NCT06384378
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505
Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease
NCT05582200
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT05660083
Phase II Clinical Trial of Interleukin-2 in AD
NCT06096090
LSTR in Chevron Osteotomy
NCT06486753
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT05305924
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
NCT06258551
Clazakizumab vs. Placebo - COVID-19 Infection
NCT04494724
Ocrelizumab for Psychosis by Autoimmunity
NCT03971487
Effect of BFR Rehab After Achilles Tendon Rupture
NCT06254794
Limb Occlusion Pressure Tourniquets to Decrease Pain After Surgery
NCT04390425
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
NCT03603405
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
NCT01913106
IO Vancomycin in TSA
NCT05831774
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 35 |
| Phase 3 | 2 |
| Phase 4 | 10 |
What is open in the The Methodist Hospital Research Institute pipeline
49 recruiting of 126 indexed (39% open); 48 completed (38%).
Phase mix: 12 late (III/IV) vs 65 early (I/II) (early-phase heavy).
Top condition: Urge Incontinence (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The Methodist Hospital Research Institute: open-pipeline peers nationwide
Peers matched on 126 registered trials and 39% open enrollment, not the therapeutic-area sidebar.
The Methodist Hospital Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 126 trials (± recruiting share)
- Stony Brook University · 127 trials · 19% recruiting
- Methodist Health System · 125 trials · 29% recruiting
- Jazz Pharmaceuticals · 128 trials · 12% recruiting
- University of Illinois at Urbana-Champaign · 129 trials · 14% recruiting
Sponsors near 39% open enrollment (± trial volume)
- argenx · 39% recruiting · 49 trials
- Morehouse School of Medicine · 38% recruiting · 13 trials
- Northeastern University · 38% recruiting · 39 trials
- Thomas Hope · 38% recruiting · 13 trials
Related
What to do with this The Methodist Hospital Research Institute page
126 registered trials is a research-attention snapshot, not an endorsement of The Methodist Hospital Research Institute or any single study.
- 49 of The Methodist Hospital Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urge Incontinence is the condition The Methodist Hospital Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urge Incontinence trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
The Methodist Hospital Research Institute pipeline card: 126 registered trials from official public datasets.Report a data error.